TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047–2063.
   PubMed Web of Science ®Google Scholar
• Koike K, Tsutsumi T, Fujie H, et al. Molecular mechanism of viral hepatocarcinogenesis. Oncology. 2002;62(Suppl. 1):29–37.
   PubMedGoogle Scholar
• Sakurai T, Maeda S, Chang L, et al. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Nat Acad Sci. 2006;103(28):10544–10551.
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Supp 4):5–13.
   PubMedGoogle Scholar
• Bahri O, Ezzikouri S, Alaya-Bouafif NB, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol. 2011;3(1):24–30.
   PubMedGoogle Scholar
• Howell J, Angus P, Gow P, et al. Toll-like receptors in hepatitis C infection: implications for pathogenesis and treatment. J Gastroenterol Hepatol. 2013;28(5):766–776.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–680.
   PubMed Web of Science ®Google Scholar
• Horner SM, Gale JM. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013;19(7):879–888.
   PubMed Web of Science ®Google Scholar
• Karimi-Googheri M, Arababadi MK. TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep. 2014;41(5):3279–3286.
   PubMed Web of Science ®Google Scholar
• Orlando de Souza PN, Keyla SGS, Barbara BS, et al. Lack of association between polymorphisms of the TLR4 gene and infection with the hepatitis B and C viruses. Mediators Inflamm. 2015;2015:7.
   Google Scholar
• Machida K, Cheng KT, Sung VMH, et al. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol. 2006;80(2):866–874.
   PubMed Web of Science ®Google Scholar
• Geng PL, Song LX, An H, et al. Toll-Like Receptor 3 is associated with the risk of HCV infection and HBV-related diseases. Medicine (Baltimore). 2016;95(21):e2302.
   PubMed Web of Science ®Google Scholar
• El-Bendary M, Neamatallah M, Elalfy HB, et al. The association of single nucleotide polymorphisms of Toll-like receptor 3, Toll-like receptor 7 and Toll-like receptor 8 genes with the susceptibility to HCV infection. Br J Biomed Sci. 2018;75:175–181.
   PubMed Web of Science ®Google Scholar
• Ding L, Jiang Q, Li G, et al. Comprehensive assessment of association between TLR4 gene polymorphisms and cancer risk: a systematic meta-analysis. Oncotarget. 2017;8(59):100593.
   PubMedGoogle Scholar
• Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS One. 2008;3(7):e2573.
   PubMed Web of Science ®Google Scholar
• Sitnik R, Pinho JR, Bertolini DA, et al. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. J Clin Microbiol. 2004;42(6):2455–2460.
   PubMed Web of Science ®Google Scholar
• Park BB, Kim JS, Lee YY, et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(1):88–94.
   PubMed Web of Science ®Google Scholar
• Amin J, Dore GJ, O’Connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol. 2006;45(2):197–203.
   PubMed Web of Science ®Google Scholar
• Tong MJ, Blatt LM, Tyson KB, et al. Death from liver disease and development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a prospective study. Gastroenterol Hepatol. 2006;2(1):41.
   Google Scholar
• Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31:9–16.
   PubMed Web of Science ®Google Scholar
• Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Nat Acad Sci. 2007;104(42):45–50.
   Web of Science ®Google Scholar
• Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204(1):11–20.
   PubMed Web of Science ®Google Scholar
• Wang N, Liang Y, Devaraj S, et al. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol. 2009;83(19):24–34.
   Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57–63.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413(6857):32–38.
   Web of Science ®Google Scholar
• Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. Rev Med Virol. 2011;21(2):67–77.
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25(2):87–91.
   PubMed Web of Science ®Google Scholar
• Pires-Neto OD, Ksg DS, Santana BB, et al. Lack of association between polymorphisms of the TLR4 gene and infection with the hepatitis B and C viruses. Mediators Inflamm. 2015;42(2):139–144.
   Google Scholar
• Alexander C, Rietschel ET. Invited review: bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2002;7(3):167–202.
   Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):17–21.
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Skinner NA, Thompson AJ, et al. Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45(1):102–110.
   PubMed Web of Science ®Google Scholar
• Naoumov NV, Schneider R, Grötzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology. 1992;102(2):38–43.
   Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124(2):27–34.
   Web of Science ®Google Scholar
• Malik A, Kumar D, Khan AA, et al. Hepatitis B virus precore G1896A mutation in chronic liver disease patients with HBeAg negative serology from North India. Saudi J Biol Sci. 2018;25(7):1257–1262.
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran D, Marie MS, et al. IL-28B rs12979860 polymorphism affects the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4. Br J Biomed Sci. 2018;75(4):175.
   PubMed Web of Science ®Google Scholar